Subtype
Lung Carcinoma
CI-CAN-00001086Explore in graph →
2,130 active trials51 approved drugs598 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001086Explore in graph →
Clinical trials
7,792 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,179)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03376191 | Apatinib in Advanced Non-squamous，NSCLC | unknown | — | 100 | Jian FangOTHER | 1 | Dec 18, 2017 | clinicaltrials |
| NCT03376737 | Study of Apatinib as the Maintenance Therapy in Advanced Lung Adenocarcinoma | unknown | Phase 2 | 120 | Henan Cancer HospitalOTHER_GOV | 1 | Dec 18, 2017 | clinicaltrials |
| NCT03135977 |
| Apatinib and Etoposide as the Maintenance Therapy in Extensive-stage Small Cell Lung Cancer After First-line Chemotherapy |
| unknown |
| Phase 2 |
| 36 |
| Sichuan Cancer Hospital and Research InstituteOTHER |
| 1 |
| Dec 7, 2017 |
| clinicaltrials |
| NCT03201146 | Apatinib Combine With Platinum-Based Doublet Chemotherapy for First-line Treatment of Advanced NSCLC | unknown | Phase 1 / Phase 2 | 48 | West China HospitalOTHER | 1 | Nov 17, 2017 | clinicaltrials |
| NCT03341494 | EGFR Mutation Positive NSCLC Patients With Gefitinib and Thalidomide | unknown | Phase 2 | 128 | Fujian Cancer HospitalOTHER_GOV | 1 | Nov 14, 2017 | clinicaltrials |
| NCT03262948 | Nab-Paclitaxel Versus Paclitaxel Plus Carboplatin in Advanced Squamous Cell Non Small Cell Lung Cancer | unknown | Phase 3 | 388 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 0 | Nov 13, 2017 | clinicaltrials |
| NCT02397239 | Comparison of Cost-effectiveness of Continuation Maintenance Therapy With Six Cycles of Pemetrexed Versus Pemetrexed Until Disease Progression for Metastatic Non-squamous Non-small-cell Lung Cancer | unknown | — | 72 | National Cheng-Kung University HospitalOTHER | 1 | Nov 6, 2017 | clinicaltrials |
| NCT03331575 | Hypofractionated vs. Conventionally Fractionated Concurrent CRT for Unresectable Stage III NSCLC(HCFCCUSN) | unknown | Phase 3 | 480 | Shanghai Chest HospitalOTHER | 1 | Nov 6, 2017 | clinicaltrials |
| NCT02714010 | EGFR-TKI Concurrent With/Without WBRT in Brain Metastasis From NSCLC | unknown | Phase 3 | 601 | Sun Yat-sen UniversityOTHER | 1 | Oct 27, 2017 | clinicaltrials |
| NCT02499614 | Crizotinib in Pretreated Metastatic Non-small-cell Lung Cancer With MET Amplification or ROS1 Translocation (METROS)(METROS) | unknown | Phase 2 | 80 | Fondazione Ricerca TraslazionaleOTHER | 1 | Oct 25, 2017 | clinicaltrials |
| NCT03198923 | Clinical Efficacy and Safety of NK and NKT Cells Infusion in Patients With Non Small Cell Lung Cancer | unknown | Phase 1 | 30 | Wenxiang WangOTHER | 1 | Sep 25, 2017 | clinicaltrials |
| NCT02455843 | Microwave Plus Chemotherapy Versus Chemotherapy for Advanced NSCLC | unknown | Phase 3 | 275 | Shandong Provincial HospitalOTHER_GOV | 1 | Sep 19, 2017 | clinicaltrials |
| NCT02894853 | Lung Cancer Early Molecular Assessment Trial(LEMA) | unknown | — | 1,297 | The Netherlands Cancer InstituteOTHER | 1 | Sep 14, 2017 | clinicaltrials |
| NCT03269162 | Postoperative NSCLC Treated With Integrated Medicine Base on Circulating Tumor Cell Detection | unknown | Phase 3 | 144 | lihegenOTHER | 0 | Sep 14, 2017 | clinicaltrials |
| NCT03282435 | Treatment of Non-small Cell Lung Cancer With Cytokine-induced Killer (CIK) Cells Blocked by PD-1 Antibody | unknown | Phase 1 | 30 | Dalian UniversityOTHER | 0 | Sep 14, 2017 | clinicaltrials |
| NCT02995187 | Study of Apatinib as Third-line and Later Therapy in Patients With Small Cell Lung Cancer (SCLC) | unknown | Phase 2 | 25 | Chinese Academy of Medical SciencesOTHER | 1 | Sep 7, 2017 | clinicaltrials |
| NCT03264794 | the Clinical Trial of Gefitinib(Non - Small Cell Lung Cancer) | unknown | Phase 4 | 100 | Jiangsu Famous Medical Technology Co., Ltd.INDUSTRY | 0 | Aug 29, 2017 | clinicaltrials |
| NCT03258671 | IMRT and Timing in Combination With EGFRTKI for Stage IV Non-small-cell Lung Cancer | unknown | N/A | 160 | LuBingOTHER | 1 | Aug 25, 2017 | clinicaltrials |
| NCT02423590 | Study of Gemcitabine/Carboplatin First-line Chemotherapy +/- Apatorsen in Advanced Squamous Cell Lung Cancers | unknown | Phase 2 | 140 | Queen Mary University of LondonOTHER | 1 | Aug 22, 2017 | clinicaltrials |
| NCT02515435 | The Efficacy and Safety of Apatinib in Heavily Pretreated Advanced Non-squamous Non-small Cell Lung Cancer | unknown | Phase 2 | 40 | Tongji UniversityOTHER | 1 | Aug 18, 2017 | clinicaltrials |
| NCT03065764 | 89Zr-labeled Pembrolizumab in Patients With Non-small-cell Lung Cancer | unknown | Phase 2 | 10 | Amsterdam UMC, location VUmcOTHER | 1 | Aug 17, 2017 | clinicaltrials |
| NCT03244904 | Next-generation Sequencing of Small Cell Lung Cancer to Identify Susceptibility Gene and to Assess Treatment | unknown | — | 80 | Fujian Cancer HospitalOTHER_GOV | 0 | Aug 10, 2017 | clinicaltrials |
| NCT02404675 | High Dose Icotinib in Advanced Non-small Cell Lung Cancer With EGFR 21 Exon Mutation(INCREASE) | unknown | Phase 4 | 240 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jul 28, 2017 | clinicaltrials |
| NCT03219762 | Study of Nab-paclitaxel in Sensitive and Refractory Relapsed SCLC(Nabster) | unknown | Phase 2 | 65 | Gruppo Oncologico Italiano di Ricerca ClinicaOTHER | 1 | Jul 26, 2017 | clinicaltrials |
| NCT03228368 | The Predicted Potential of Quantitative T Cell Repertoire(TCR) in Anti-PD-L1 Treatment in NSCLC Patients | unknown | — | 10 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Jul 24, 2017 | clinicaltrials |
| NCT01014130 | Hypofractionated Radiotherapy (Stereotactic) Versus Conventional Radiotherapy for Inoperable Early Stage I Non-small Cell Lung Cancer (NSCLC)(CHISEL) | unknown | Phase 3 | 101 | Trans Tasman Radiation Oncology GroupOTHER | 2 | Jul 12, 2017 | clinicaltrials |
| NCT03205930 | Neo-MASCT Immunotherapy for Advanced NSCLC. | unknown | Phase 1 / Phase 2 | 20 | The First People's Hospital of LianyungangOTHER | 1 | Jul 5, 2017 | clinicaltrials |
| NCT03195569 | To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in Study of QL1101 and Avastin® in Patients With Non-squamous Non-small Cell Lung Cancer | unknown | — | 15 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 22, 2017 | clinicaltrials |
| NCT02896166 | Microwave Ablation in the Treatment of Stage I Non Small Cell Lung Cancer | unknown | Phase 3 | 150 | Shandong Provincial HospitalOTHER_GOV | 1 | Jun 14, 2017 | clinicaltrials |
| NCT02381808 | Study on Potential Biomarkers Associated With Clinical Phenotype of EGFR-TKIs in No-small Cell Lung Cancer in China | unknown | — | 150 | Guangdong Association of Clinical TrialsOTHER | 1 | Jun 7, 2017 | clinicaltrials |
| NCT03154242 | Effect of Genetic Polymorphisms on Platinum Based Chemotherapy in Non Small Cell Lung Cancer | unknown | — | 60 | Ain Shams UniversityOTHER | 1 | May 16, 2017 | clinicaltrials |
| NCT01963195 | Evaluation of the High Dose of Icotinib in Advanced Lung Cancer Patients After Failure of Target Therapy | unknown | Phase 2 | 30 | Anhui Medical UniversityOTHER | 1 | May 8, 2017 | clinicaltrials |
| NCT03123445 | Endostar First-line Treatment of Advanced NSCLC | unknown | Phase 2 | 150 | China Medical University, ChinaOTHER | 0 | Apr 21, 2017 | clinicaltrials |
| NCT03123484 | β-elemene Combine With EGFR-TKI for Advanced EGFR-TKI-resistant NSCLC | unknown | Phase 2 | 80 | China Medical University, ChinaOTHER | 0 | Apr 21, 2017 | clinicaltrials |
| NCT02577627 | Multi-Indication, Retrospective Oncological Study to Validate the Accuracy in Predicting TTP by PrediCare in Patients Under SOC | unknown | — | 5,000 | Optimata Ltd.INDUSTRY | 1 | Apr 4, 2017 | clinicaltrials |
| NCT02844114 | Clinical Study of Ganoderma Lucidum Spore Combined With Chemotherapy(LCKY2015-21(x)) | unknown | Phase 2 | 60 | Gao YajieOTHER | 1 | Mar 31, 2017 | clinicaltrials |
| NCT03090815 | Circulating Tumor DNA (ctDNA) as a Prognostic Tool in Patients With Advanced Lung Adenocarcinoma | unknown | — | 100 | The University of Hong KongOTHER | 1 | Mar 27, 2017 | clinicaltrials |
| NCT02714608 | A Study of Ginsenoside H Dripping Pills for Advanced Non-Small Cell Lung Cancer (NSCLC) | unknown | Phase 2 | 144 | Tasly Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 21, 2017 | clinicaltrials |
| NCT02951611 | Effects of Acupuncture Stimulation on Systemic Inflammation | unknown | N/A | 60 | RenJi HospitalOTHER | 1 | Mar 17, 2017 | clinicaltrials |
| NCT03078959 | Prognostic Value of PD-L1 in NSCLC | unknown | — | 350 | Fondazione Ricerca TraslazionaleOTHER | 0 | Mar 14, 2017 | clinicaltrials |
| NCT02441972 | Clinic Study of 18F-Al-NOTA-PRGD2 in Cancer Diagnostics | unknown | Phase 1 | 200 | Wuxi No. 4 People's HospitalOTHER | 1 | Mar 10, 2017 | clinicaltrials |
| NCT02695550 | Study of Safety, Efficacy and Pharmacokinetics of CT-707 in Patients With ALK-positive Non-small Cell Lung Cancer | unknown | Phase 1 | 40 | Centaurus Biopharma Co., Ltd.INDUSTRY | 1 | Mar 9, 2017 | clinicaltrials |
| NCT03074864 | Targeted Treatment With Intercalated Radiotherapy in EGFR-mutant IIIA/IIIB NSCLC(TREND) | unknown | Phase 2 / Phase 3 | 90 | Guangdong Provincial People's HospitalOTHER | 1 | Mar 9, 2017 | clinicaltrials |
| NCT02055144 | Veristrat as Predictor of Benefit of First Line Non Small Cell Lung Cancer (NSCLC) Patients From Standard Chemotherapy | unknown | — | 100 | IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, ItalyOTHER | 1 | Mar 7, 2017 | clinicaltrials |
| NCT01980472 | Chemotherapy Plus Bevacizumab in Elderly Non-small Cell Lung Cancer Patients | unknown | Phase 2 | 50 | Grupo de Investigación y Divulgación OncológicaOTHER | 1 | Feb 27, 2017 | clinicaltrials |
| NCT02282267 | Blood Detection of EGFR Mutation For Iressa Treatment(Benefit) | unknown | N/A | 188 | Peking University Cancer Hospital & InstituteOTHER | 1 | Feb 24, 2017 | clinicaltrials |
| NCT02332512 | Study of Apatinib as 3rd/4th Line Treatment in Patients With Advanced Non-Squamous Non-small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor (EGFR)(ANSWER) | unknown | Phase 3 | 417 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 24, 2017 | clinicaltrials |
| NCT03060343 | Zeushield Cytotoxic T Lymphocytes (Z-CTLs) for Relapsed or Refractory Non Small Cell Lung Cancer (NSCLC) | unknown | Early Phase 1 | 10 | Yu FengleiOTHER | 1 | Feb 23, 2017 | clinicaltrials |
| NCT03057340 | The Treatment of Advanced Lung Cancer With Dribbles Antigen by Targeting Activation of Tcells | unknown | Phase 1 | 30 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 0 | Feb 20, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Dec 18, 2017source: clinicaltrials